Insider Trading Alert - LPNT, PATK And CTIC Traded By Insiders

Friday, May 27, 2016, 78 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $10.48 to $15,949,248.85.

Highlighted Stocks Traded by Insiders:

LifePoint Health (LPNT) - FREE Research Report

Maupin John E Jr D D S, who is Director at LifePoint Health, sold 3,800 shares at $67.32 on May 27, 2016. Following this transaction, the Director owned 22,813 shares meaning that the stake was reduced by 14.28% with the 3,800-share transaction.

The shares most recently traded at $66.38, down $0.94, or 1.42% since the insider transaction. Historical insider transactions for LifePoint Health go as follows:

  • 4-Week # shares sold: 3,800
  • 12-Week # shares sold: 3,800
  • 24-Week # shares sold: 5,949

The average volume for LifePoint Health has been 373,400 shares per day over the past 30 days. LifePoint Health has a market cap of $2.9 billion and is part of the health care sector and health services industry. Shares are down 9.47% year-to-date as of the close of trading on Friday.

LifePoint Health, Inc., through its subsidiaries, owns and operates community hospitals, regional health systems, physician practices, outpatient centers, and post-acute facilities in the United States. The company has a P/E ratio of 18.5. Currently, there are 5 analysts who rate LifePoint Health a buy, 1 analyst rates it a sell, and 11 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LPNT - FREE

TheStreet Quant Ratings rates LifePoint Health as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, reasonable valuation levels and notable return on equity. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full LifePoint Health Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Patrick Industries (PATK) - FREE Research Report

Nemeth Andy L, who is President at Patrick Industries, sold 20,000 shares at $53.00 on May 27, 2016. Following this transaction, the President owned 72,010 shares meaning that the stake was reduced by 21.74% with the 20,000-share transaction.

Rodino Jeff, who is EVP-Sales & COO at Patrick Industries, sold 10,000 shares at $53.01 on May 27, 2016. Following this transaction, the EVP-Sales & COO owned 61,647 shares meaning that the stake was reduced by 13.96% with the 10,000-share transaction.

The shares most recently traded at $52.86, down $0.15, or 0.28% since the insider transaction. Historical insider transactions for Patrick Industries go as follows:

  • 4-Week # shares bought: 9,800
  • 4-Week # shares sold: 44,870
  • 12-Week # shares bought: 9,800
  • 12-Week # shares sold: 111,943
  • 24-Week # shares bought: 9,800
  • 24-Week # shares sold: 152,323

The average volume for Patrick Industries has been 152,300 shares per day over the past 30 days. Patrick Industries has a market cap of $815.9 million and is part of the industrial goods sector and materials & construction industry. Shares are up 22.6% year-to-date as of the close of trading on Friday.

Patrick Industries, Inc. manufactures and distributes building products and materials for the recreational vehicle, manufactured housing, and industrial markets in the United States and Canada. The company has a P/E ratio of 18.2. Currently, there is 1 analyst who rates Patrick Industries a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on PATK - FREE

TheStreet Quant Ratings rates Patrick Industries as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, attractive valuation levels and good cash flow from operations. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full Patrick Industries Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Cell Therapeutics (CTIC) - FREE Research Report

Bianco James A, who is President and CEO at Cell Therapeutics, sold 10,000 shares at $0.45 on May 27, 2016. Following this transaction, the President and CEO owned 1.8 million shares meaning that the stake was reduced by 0.56% with the 10,000-share transaction.

The shares most recently traded at $3.01, up $2.56, or 85.15% since the insider transaction. Historical insider transactions for Cell Therapeutics go as follows:

  • 4-Week # shares bought: 934,623
  • 4-Week # shares sold: 10,000
  • 12-Week # shares bought: 934,623
  • 12-Week # shares sold: 348,169
  • 24-Week # shares bought: 934,623
  • 24-Week # shares sold: 653,169

The average volume for Cell Therapeutics has been 3.7 million shares per day over the past 30 days. Cell Therapeutics has a market cap of $440.5 million and is part of the health care sector and drugs industry. Shares are up 53.93% year-to-date as of the close of trading on Tuesday.

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally.

Exclusive Offer: Get the latest Stock Analysis on CTIC - FREE

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Don't Panic! The Risk of a Recession This Year Is Low

Don't Panic! The Risk of a Recession This Year Is Low

Even Standing Desk Company Varidesk Is Watching How the Trump Tariffs Play Out

Even Standing Desk Company Varidesk Is Watching How the Trump Tariffs Play Out

State Street Gets Pummeled on Software Deal; Pizza Wars Are Raging -- ICYMI

State Street Gets Pummeled on Software Deal; Pizza Wars Are Raging -- ICYMI

Schlumberger Stock Dips as Investors Ignore Start of 'Earnings Liftoff'

Schlumberger Stock Dips as Investors Ignore Start of 'Earnings Liftoff'

GSK Shares Climb as Board Is Said to Mull Breakup of Pharma Giant

GSK Shares Climb as Board Is Said to Mull Breakup of Pharma Giant